Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Silacci-Fregni C"" wg kryterium: Autor


Wyświetlanie 1-19 z 19
Tytuł:
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
Autorzy:
Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Pinto D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
De Marco A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Benigni F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Zatta F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Silacci-Fregni C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bassi J; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Addetia A; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Stewart C; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Giurdanella M; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Saliba C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Guarino B; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Schmid MA; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Logue JK; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Dang HV; Vir Biotechnology, San Francisco, CA, USA.
Hauser K; Vir Biotechnology, San Francisco, CA, USA.
di Iulio J; Vir Biotechnology, San Francisco, CA, USA.
Rivera W; Vir Biotechnology, San Francisco, CA, USA.
Schnell G; Vir Biotechnology, San Francisco, CA, USA.
Rajesh A; Vir Biotechnology, San Francisco, CA, USA.
Zhou J; Vir Biotechnology, San Francisco, CA, USA.
Farhat N; Vir Biotechnology, San Francisco, CA, USA.
Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
Noack J; Vir Biotechnology, San Francisco, CA, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
Janer J; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Abdelnabi R; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Maes P; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.
Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
de Melo GD; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Kergoat L; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Bourhy H; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Soriaga L; Vir Biotechnology, San Francisco, CA, USA.
Purcell LA; Vir Biotechnology, San Francisco, CA, USA.
Snell G; Vir Biotechnology, San Francisco, CA, USA.
Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Lanzavecchia A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Piccoli L; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Pizzuto MS; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Corti D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Nov 11; Vol. 378 (6620), pp. 619-627. Date of Electronic Publication: 2022 Oct 20.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/immunology
Antibody Formation*
COVID-19*/immunology
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*
Immune Evasion*
Humans ; Neutralization Tests ; Immunologic Memory ; Memory B Cells/immunology
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Tytuł:
Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Autorzy:
Collier DA; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK.
De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Ferreira IATM; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.
Meng B; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.
Datir RP; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Kemp SA; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK.
Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Silacci-Fregni C; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Bowen J; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Snell G; Vir Biotechnology, San Francisco, CA, USA.
Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Pellanda AF; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
Riva A; Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy.
Elmer A; NIHR Cambridge Clinical Research Facility, Cambridge, UK.
Kingston N; NIHR Bioresource, Cambridge, UK.
Graves B; NIHR Bioresource, Cambridge, UK.
McCoy LE; Division of Infection and Immunity, University College London, London, UK.
Smith KGC; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.
Bradley JR; Department of Medicine, University of Cambridge, Cambridge, UK.; NIHR Bioresource, Cambridge, UK.
Temperton N; University of Kent, Canturbury, UK.
Ceron-Gutierrez L; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.
Barcenas-Morales G; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.; Laboratorio de Inmunologia, UNAM, Cuautitlán, Mexico.
Harvey W; Institute of Biodiversity, University of Glasgow, Glasgow, UK.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.
Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Doffinger R; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.; Department of Haematology, University of Cambridge, Cambridge, UK.
Wills M; Department of Medicine, University of Cambridge, Cambridge, UK.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. .
Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Cambridge, UK. .; Department of Medicine, University of Cambridge, Cambridge, UK. .; Department of Haematology, University of Cambridge, Cambridge, UK. .; University of KwaZulu Natal, Durban, South Africa. .; Africa Health Research Institute, Durban, South Africa. .; Department of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge, UK. .
Pokaż więcej
Corporate Authors:
CITIID-NIHR BioResource COVID-19 Collaboration
COVID-19 Genomics UK (COG-UK) Consortium
Źródło:
Nature [Nature] 2022 Aug; Vol. 608 (7922), pp. E24.
Typ publikacji:
Published Erratum
    Wyświetlanie 1-19 z 19

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies